RTOG 0920, “A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer,” will close to accrual at 5 PM ET Tuesday, March 27, 2018, because it has reached its accrual target. All patients registered to Step 1 registration by March 27 will be permitted to proceed to the randomization step (Step 2).

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.



View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103